Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544406 | 1.00 | CYP1A2 (0.47) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL19708766 | 0.85 | CYP1A2 (0.47) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL19544407 | 0.83 | CYP1A2 (0.46) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL14755874 | 0.81 | CYP1A2 (0.47) | CYP1A2ALDH1A1ACKR3 | |
| SCHEMBL20050543 | 0.81 | CYP1A2 (0.47) | CYP1A2ALDH1A1ACKR3 | |
| SCHEMBL22277150 | 0.80 | ACKR3 (0.45) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| Hygrine SCHEMBL335690 | 0.80 | CHRNB2 (0.44) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| Hygrine SCHEMBL335689 | 0.80 | CHRNB2 (0.44) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| Acetic Acid SCHEMBL30330984 | 0.79 | CYP1A2 (0.46) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL18688759 | 0.79 | CYP1A2 (0.55) | CYP1A2CHRNB2CHRNA7CHRNA4CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | CYP1A2 2434/4885CHRNB2 1570/4885CHRNA7 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.